These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 18614977)

  • 1. New insights into Lactobacillus and functional intestinal disorders.
    Lombardo L
    Minerva Gastroenterol Dietol; 2008 Sep; 54(3):287-93. PubMed ID: 18614977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probiotics and irritable bowel syndrome: rationale and clinical evidence for their use.
    Barbara G; Stanghellini V; Cremon C; De Giorgio R; Gargano L; Cogliandro R; Pallotti F; Corinaldesi R
    J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 2():S214-7. PubMed ID: 18685517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Probiotics and irritable bowel syndrome: rationale, mechanisms, and efficacy.
    Camilleri M
    J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 1():S123-5. PubMed ID: 18806702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Lactobacillus probiotics for bacterial genitourinary infections in women: a review.
    Barrons R; Tassone D
    Clin Ther; 2008 Mar; 30(3):453-68. PubMed ID: 18405785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The rationale and clinical effectiveness of probiotics in irritable bowel syndrome.
    Ringel Y; Ringel-Kulka T
    J Clin Gastroenterol; 2011 Nov; 45 Suppl():S145-8. PubMed ID: 21992954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome.
    Barbara G; Zecchi L; Barbaro R; Cremon C; Bellacosa L; Marcellini M; De Giorgio R; Corinaldesi R; Stanghellini V
    J Clin Gastroenterol; 2012 Oct; 46 Suppl():S52-5. PubMed ID: 22955358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transgenomic metabolic interactions in a mouse disease model: interactions of Trichinella spiralis infection with dietary Lactobacillus paracasei supplementation.
    Martin FP; Verdu EF; Wang Y; Dumas ME; Yap IK; Cloarec O; Bergonzelli GE; Corthesy-Theulaz I; Kochhar S; Holmes E; Lindon JC; Collins SM; Nicholson JK
    J Proteome Res; 2006 Sep; 5(9):2185-93. PubMed ID: 16944930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probiotics in functional gastrointestinal disorders: what are the facts?
    Quigley EM
    Curr Opin Pharmacol; 2008 Dec; 8(6):704-8. PubMed ID: 18775516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review article: probiotics for the treatment of irritable bowel syndrome--focus on lactic acid bacteria.
    Clarke G; Cryan JF; Dinan TG; Quigley EM
    Aliment Pharmacol Ther; 2012 Feb; 35(4):403-13. PubMed ID: 22225517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review article: probiotics and prebiotics in irritable bowel syndrome.
    Spiller R
    Aliment Pharmacol Ther; 2008 Aug; 28(4):385-96. PubMed ID: 18532993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of oral lactobacilli as potential probiotics for oral health.
    Kõll P; Mändar R; Marcotte H; Leibur E; Mikelsaar M; Hammarström L
    Oral Microbiol Immunol; 2008 Apr; 23(2):139-47. PubMed ID: 18279182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probiotics in functional intestinal disorders and IBS: proof of action and dissecting the multiple mechanisms.
    Marteau P
    Gut; 2010 Mar; 59(3):285-6. PubMed ID: 20207630
    [No Abstract]   [Full Text] [Related]  

  • 13. The efficacy of probiotics in IBS.
    Quigley EM
    J Clin Gastroenterol; 2008 Jul; 42 Suppl 2():S85-90. PubMed ID: 18542036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of probiotics in the treatment of irritable bowel syndrome.
    Wilhelm SM; Brubaker CM; Varcak EA; Kale-Pradhan PB
    Pharmacotherapy; 2008 Apr; 28(4):496-505. PubMed ID: 18363533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: a multicenter, randomized study.
    Andriulli A; Neri M; Loguercio C; Terreni N; Merla A; Cardarella MP; Federico A; Chilovi F; Milandri GL; De Bona M; Cavenati S; Gullini S; Abbiati R; Garbagna N; Cerutti R; Grossi E
    J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 2():S218-23. PubMed ID: 18685503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacterial flora in irritable bowel syndrome: role in pathophysiology, implications for management.
    Quigley EM
    J Dig Dis; 2007 Feb; 8(1):2-7. PubMed ID: 17261128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of irritable bowel syndrome with probiotics. An etiopathogenic approach at last?
    Bixquert Jiménez M
    Rev Esp Enferm Dig; 2009 Aug; 101(8):553-64. PubMed ID: 19785495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome.
    Zeng J; Li YQ; Zuo XL; Zhen YB; Yang J; Liu CH
    Aliment Pharmacol Ther; 2008 Oct; 28(8):994-1002. PubMed ID: 18671775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date.
    Quigley EM; Flourie B
    Neurogastroenterol Motil; 2007 Mar; 19(3):166-72. PubMed ID: 17300285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Almost all irritable bowel syndromes are post-infectious and respond to probiotics: consensus issues.
    Cuomo R; Savarese MF; Gargano R
    Dig Dis; 2007; 25(3):241-4. PubMed ID: 17827948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.